Table 1 Baseline characteristics of study participants
healthy controls (n = 30) | Sjögren’s syndrome (n = 30) | |
|---|---|---|
age (year, mean ± SD) | 51.6 ± 10.2 | 51.3 ± 10.2 |
women (n, %) | 28 (93) | 29 (97) |
smoking (n, %) | 0 (0) | 0 (0) |
comorbid disease (n, %) | ||
hypertension | 5 (17) | 4 (13) |
diabetes mellitus | 0 (0) | 0 (0) |
chronic kidney disease | 0 (0) | 0 (0) |
liver cirrhosis | 0 (0) | 1 (3) |
autoimmune disease (including Sjögren’s syndrome) | 0 (0) | 30 (100) |
duration of xerostomia (year, mean ± SD) | 0 ± 0 | 5.6 ± 4.5 |
unstimulated whole salivary flow rate (ml/min, mean ± SD) | 0.50 ± 0.28 | 0.17 ± 0.12 |
hyposalivation (n, %) | 0 (0) | 11 (37) |
Schirmer’s test ≤ 5 mm (n, %) | NA | 29 (97) |
ESSDAI (point, mean ± SD) | NA | 4.4 ± 2.8 |
anti-Ro positivity (n, %) | NA | 20 (67) |
IgG (mg/dL, mean ± SD) | NA | 1481 ± 541 |
received LSG biopsy with focus score ≥ 1 (n, %) | NA | 10 (33) |
medication (n, %) | ||
hydroxychloroquine | 0 (0) | 17 (57) |
sulfasalazine | 0 (0) | 2 (7) |
methotrexate | 0 (0) | 2 (7) |
cyclosporin | 0 (0) | 1 (3) |
azathioprine | 0 (0) | 2 (7) |
corticosteroids | 0 (0) | 7 (23) |
secretagogues | 0 (0) | 6 (20) |
